A5066851087- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Inflammatory Biomarkers in Disease Prognosis
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
- Extracellular vesicles in disease
- Economic and Financial Impacts of Cancer
- HER2/EGFR in Cancer Research
- Prostate Cancer Treatment and Research
- Nutrition and Health in Aging
- Multiple and Secondary Primary Cancers
- Urinary and Genital Oncology Studies
- Hypothalamic control of reproductive hormones
- Cancer Risks and Factors
- Radiopharmaceutical Chemistry and Applications
- Cancer survivorship and care
- Estrogen and related hormone effects
- Colorectal and Anal Carcinomas
- Medical Imaging Techniques and Applications
- Brain Metastases and Treatment
Ospedale Santa Corona
2023-2025
University of Modena and Reggio Emilia
2018-2024
Azienda Ospedaliero-Universitaria di Modena
2021-2023
University of Messina
2023
Renal cell carcinoma (RCC) is one of the most common types urogenital cancer. The introduction immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase (TKIs), has radically changed treatment landscape for metastatic RCC, showing varying efficacy across different prognostic groups based on International Metastatic RCC Database Consortium (IMDC) criteria. This retrospective multicenter study, part ARON-1 project, aimed to evaluate outcomes...
The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated first-line immunotherapy combinations (TKI plus ICI or ICI). We performed a sub-analysis multicenter retrospective observational (ARON-1 project) involving combinations. Three hundred twenty-nine were enrolled, 244 males 85 females. Median age was 65.5 years. impact on PFS OS observed whole population examined. had correlation neutrophil-to-lymphocyte (NLR), blood...
TPS617 Background: At diagnosis, 55% of RCC are localized, and 25% locally advanced/metastatic (aRCC); an additional 30% develop metastases during follow-up. Prognosis is highly variable in both resectable advanced disease. All patients’ stratification tools based on clinical risk scores. For resected patients, only pembrolizumab has demonstrated OS benefit the adjuvant setting. metastatic disease, first-line combos (IO-IO IO-TKI) have dramatically improved outcomes intermediate/poor-risk...
ABSTRACT Background The therapeutic management of metastatic hormone‐sensitive prostate cancer (mHSPC) is still based on clinical and pathological parameters due to the lack biomarkers that may drive tailored treatment. Methods In this non‐randomized, single‐center, retrospective trial, we searched for a genetic signature using NanoString nCounter PanCancer Pathways Panel formalin‐fixed paraffin embedded samples belonging 48 patients with de novo or relapsed mHSPC. Patients were divided into...
Immunotherapy combinations with tyrosine-kinase inhibitors (TKIs) and immune checkpoint (ICIs) had significantly improved outcomes of patients mRCC. Predictive prognostic factors are crucial to improve patients' counseling management. The present study aimed externally validate the value a previously developed red cell-based score, including hemoglobin (Hb), mean corpuscular volume (MCV) cell distribution width (RDW), in mRCC treated first-line immunotherapy (TKI plus ICI or ICI). We...
Fat tissue is strongly involved in BC tumorigenesis inducing insulin resistance, chronic inflammation and hormonal changes. Computed tomography (CT) imaging instead of body mass index (BMI) gives a reliable measure skeletal muscle fat distribution. The impact composition parameters (BCPs) on chemosensitivity still debated. We examined the associations between BCPs tumor response to neoadjuvant chemotherapy (NC) patients treated for operable breast cancer (BC).A retrospective review with NC...
Neutrophil-to-eosinophil ratio (NER) has been described to be associated with outcomes immune checkpoint inhibitors (ICI) in several tumor types, but less is known about its role of the response avelumab advanced urothelial cancer (aUC). Thus, we reported by NER aUC patients treated as maintenance after initial platinum-based chemotherapy and enrolled Maintenance AVeLumAb ([MALVA] neoplasms first-line chemotherapy: an observational retrospective study) study (Meet-URO 25).
Ovarian cancer is metastatic at presentation in about 62% of cases, but brain metastases are rare, reported 3.3-4% patients. Brain metastasis seems to be more frequent advanced stages diagnosis and patients with BRCA1/2 mutation.We present a case 47-year-old Caucasian woman, BRCA wild type, an ovarian that started single cerebellar metastasis.Brain rare complex for management. This focuses both on treatment, emphasizing the importance multimodal approach multidisciplinary team.
Everolimus has been shown to overcome endocrine resistance in hormone receptor positive advanced breast cancer patients. Predictive biomarkers of everolimus efficacy have investigated primary tissue without finding univocal results. The goal this study was investigate the mutational burden metastatic site endocrine-resistant tumors treated with plus exemestane.Mass Array Sequenom platform used analyse genetic status 18 cancer-related genes 25 archival tumor specimens from lesions and...
Introduction Central precocious puberty (CPP) results from premature activation of hypothalamic-pituitary-gonadal axis, with the consequent increase gonadotropin-releasing hormone (GnRH); GnRH agonists (GnRHa) represent gold-standard therapy in children CPP although their use might be responsible for pituitary receptors down-regulation, that turn suppresses luteinizing (LH) and follicle stimulating (FSH) blocks gonadal sex hormones release. The most prescribed GnRHa clinical practice are...
TPS485 Background: Nowadays, different systemic treatments are available for the first-line setting of metastatic renal cell carcinoma (mRCC). Immuno-combinations standard therapy in all mRCC patients regardless IMDC risk category, even though TKI monotherapy is still a therapeutic option selected patients. However, comparisons between treatment strategies lacking and few real-world data this setting. For these reasons, regimen choice represents an important issue clinical practice optimal...
Vaginal cancer is a rare gynecologic malignancy. While in localized disease, concurrent chemoradiation grants local control and better overall survival, metastatic setting, the management options are very limited. Furthermore, recurrent cervical, vulvar, vaginal carcinomas notoriously develop resistance to treatment, consequently, their prognosis still poor.
Renal cell carcinoma (RCC) is the second most common cancer of urinary system. The current therapeutic strategies are based on partial or total nephrectomy and/or targeted therapies immune checkpoint inhibitors to which patients often refractory. Preventive and screening not existing few available biomarkers for RCC characterized by lack sensitivity, outlining need novel noninvasive sensitive an early diag-nosis a better disease monitoring. Blood liquid biopsy (LB) non- minimally invasive...
Renal cell carcinoma accounts for 3% of all tumors. Over the last decades, prognosis metastatic renal (mRCC) has improved owing to approval several drugs such as tyrosine kinase inhibitors and immunotherapy. The median progression-free survival (PFS) does not exceed 8 months with available in pretreated patients mRCC. We present a case patient long-term response fourth-line treatment cabozantinib. Our obtained PFS 33 months, which is much higher than that reported literature.
1046 Background: Combined endocrine approaches have been widely investigated as first-line treatment in hormone receptors positive metastatic breast cancer. In particular, multiple randomized trials showed that the addiction of CDK (cyclin-dependent kinase) 4/6 inhibitors to therapy (ET) increase progression free survival (PFS). Elderly patients (aged ≥65 years) are under represented most clinical studies. Moreover, due multi-morbidity and major toxicity associated with targeted agents,...